Drug intelligence / Profile preview

ofloxacin + metronidazole

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Ofloxacin + metronidazole is a fixed-dose combination medication containing two active pharmaceutical ingredients: ofloxacin (a fluoroquinolone antibiotic) and metronidazole (a nitroimidazole-class antiprotozoal and antibacterial agent). This combination is used to treat a variety of mixed bacterial and protozoal infections, particularly in the gastrointestinal tract (such as diarrhea and dysentery), genitourinary tract, respiratory system, skin/soft tissue infections, pelvic inflammatory disease, bacterial vaginosis, gynecological infections, dental abscesses/infections, intra-abdominal infections, and post-surgical infections[1][3][4][5]. - Ofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes involved in DNA replication—preventing cell division and leading to bactericidal activity against susceptible bacteria. - Metronidazole works by entering anaerobic bacteria/protozoa cells where it disrupts their DNA structure through reduction reactions—resulting in cell death. It is effective against anaerobic bacteria as well as protozoan parasites such as Entamoeba histolytica[1][4][5]. The combination provides broad-spectrum coverage for mixed aerobic-anaerobic or protozoal-bacterial infections. Both drugs are small molecules administered orally or via suspension formulations.

Brand names
Diof SuspensionNew Normetother regional or generic brands
Other names
ofloxacin with metronidazoleofloxacin and metronidazole
02

Targets

DNA gyraseTopo IV (Bacterial Topoisomerase IV)Neuraminidase

Beyond the preview

Go deeper on ofloxacin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ofloxacin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call